AU2017242027B2 - Estrogen receptor modulators - Google Patents

Estrogen receptor modulators Download PDF

Info

Publication number
AU2017242027B2
AU2017242027B2 AU2017242027A AU2017242027A AU2017242027B2 AU 2017242027 B2 AU2017242027 B2 AU 2017242027B2 AU 2017242027 A AU2017242027 A AU 2017242027A AU 2017242027 A AU2017242027 A AU 2017242027A AU 2017242027 B2 AU2017242027 B2 AU 2017242027B2
Authority
AU
Australia
Prior art keywords
mmol
compound
indol
methyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017242027A
Other languages
English (en)
Other versions
AU2017242027A1 (en
Inventor
Kevin Duane Bunker
Sayee Gajanan Hegde
Chad Daniel Hopkins
Peter Qinhua HUANG
Joseph Robert Pinchman
Rakesh Kumar Sit
Deborah Helen Slee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recurium IP Holdings LLC
Original Assignee
Recurium IP Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium IP Holdings LLC filed Critical Recurium IP Holdings LLC
Publication of AU2017242027A1 publication Critical patent/AU2017242027A1/en
Assigned to RECURIUM IP HOLDINGS, LLC reassignment RECURIUM IP HOLDINGS, LLC Amend patent request/document other than specification (104) Assignors: Zeno Royalties & Milestones, LLC
Application granted granted Critical
Publication of AU2017242027B2 publication Critical patent/AU2017242027B2/en
Priority to AU2020294196A priority Critical patent/AU2020294196B2/en
Priority to AU2022204025A priority patent/AU2022204025A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/60—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members
    • C07C2603/62—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members containing three- or four-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2017242027A 2016-04-01 2017-03-29 Estrogen receptor modulators Active AU2017242027B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020294196A AU2020294196B2 (en) 2016-04-01 2020-12-22 Estrogen receptor modulators
AU2022204025A AU2022204025A1 (en) 2016-04-01 2022-06-09 Estrogen receptor modulators

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317254P 2016-04-01 2016-04-01
US62/317,254 2016-04-01
PCT/US2017/024809 WO2017172957A1 (en) 2016-04-01 2017-03-29 Estrogen receptor modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020294196A Division AU2020294196B2 (en) 2016-04-01 2020-12-22 Estrogen receptor modulators

Publications (2)

Publication Number Publication Date
AU2017242027A1 AU2017242027A1 (en) 2018-10-11
AU2017242027B2 true AU2017242027B2 (en) 2020-10-08

Family

ID=59966438

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017242027A Active AU2017242027B2 (en) 2016-04-01 2017-03-29 Estrogen receptor modulators
AU2020294196A Active AU2020294196B2 (en) 2016-04-01 2020-12-22 Estrogen receptor modulators
AU2022204025A Abandoned AU2022204025A1 (en) 2016-04-01 2022-06-09 Estrogen receptor modulators

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020294196A Active AU2020294196B2 (en) 2016-04-01 2020-12-22 Estrogen receptor modulators
AU2022204025A Abandoned AU2022204025A1 (en) 2016-04-01 2022-06-09 Estrogen receptor modulators

Country Status (15)

Country Link
US (5) US20190142811A1 (https=)
EP (1) EP3442971B1 (https=)
JP (2) JP6926189B2 (https=)
KR (2) KR102401841B1 (https=)
CN (4) CN112745316A (https=)
AR (1) AR108011A1 (https=)
AU (3) AU2017242027B2 (https=)
CA (1) CA3017388C (https=)
ES (1) ES2991862T3 (https=)
IL (3) IL295050A (https=)
MX (2) MX392461B (https=)
RU (1) RU2738646C2 (https=)
SG (1) SG11201807708SA (https=)
TW (2) TW202235418A (https=)
WO (1) WO2017172957A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109362222B (zh) 2016-02-05 2021-03-19 益方生物科技(上海)股份有限公司 选择性雌激素受体降解物及其用途
CN112745316A (zh) * 2016-04-01 2021-05-04 里科瑞尔姆Ip控股有限责任公司 雌激素受体调节剂
CN107814798B (zh) * 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
WO2018130124A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
SG11202001733VA (en) 2017-09-11 2020-03-30 Recurium Ip Holdings Llc Continuous flow processes for making bicyclic compounds
CN111315378A (zh) * 2017-11-16 2020-06-19 诺华股份有限公司 包含lsz102和瑞博西尼的药物组合
CN114929696A (zh) * 2019-05-24 2022-08-19 浙江海正药业股份有限公司 丙烯酸类衍生物的晶型及其制备方法和用途
CA3148221A1 (en) * 2019-08-06 2021-02-11 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
US20220389006A1 (en) * 2019-11-04 2022-12-08 Recurium Ip Holdings, Llc Salts and forms of an estrogen receptor modulator
JP2023508324A (ja) * 2019-12-20 2023-03-02 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 組み合わせ
BR112022012280A2 (pt) * 2019-12-20 2022-08-30 Recurium Ip Holdings Llc Combinações
WO2021127042A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
KR20220119657A (ko) 2019-12-20 2022-08-30 리커리엄 아이피 홀딩스, 엘엘씨 조합
WO2021127046A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
MX2022012828A (es) * 2020-04-22 2023-01-04 Recurium Ip Holdings Llc Preparación de un degradador selectivo de receptores de estrógeno.
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
CA3192617A1 (en) * 2020-09-20 2022-03-24 Matthew BAGGOTT Advantageous tryptamine compositions for mental disorders or enhancement
WO2022133446A1 (en) * 2020-12-16 2022-06-23 Recurium Ip Holdings, Llc Combinations
EP4267578A4 (en) 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
IL309986A (en) * 2021-07-08 2024-03-01 Olema Pharmaceuticals Inc Methods of treating estrogen receptor-associated diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014191726A1 (en) * 2013-05-28 2014-12-04 Astrazeneca Ab Chemical compounds

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1148340A (zh) 1994-03-11 1997-04-23 伊莱利利公司 治疗与5htzb受体有关病症的方法
GB9604996D0 (en) 1996-03-08 1996-05-08 Black James Foundation Benzodiazonine derivatives
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
ATE348828T1 (de) 2001-10-19 2007-01-15 Transtech Pharma Inc Beta-carbolin-derivate als ptp-inhibitoren
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US20080103164A1 (en) 2004-08-02 2008-05-01 Kristjan Gudmundsson Useful compounds for hpv infection
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
CA2656067C (en) 2006-06-23 2014-08-12 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
US20100158858A1 (en) 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
DE102007028515A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
TW201028414A (en) 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
US20120202801A1 (en) * 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
MX373926B (es) * 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
HUE028874T2 (en) * 2009-07-28 2017-01-30 Ono Pharmaceutical Co Bicyclic Compound and Use Thereof for Medical Purposes
CN102695414A (zh) 2010-01-15 2012-09-26 默沙东公司 作为抗糖尿病化合物的噁二唑β-咔啉衍生物
ES2674745T3 (es) * 2010-02-11 2018-07-03 Bristol-Myers Squibb Company Macrociclos como inhibidores del factor XIa
WO2011103487A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
US9029574B2 (en) * 2011-01-27 2015-05-12 Ono Pharmaceutical Co., Ltd. Bicyclic compound and use thereof for medical purposes
CN102432608B (zh) 2011-11-01 2013-04-17 浙江大学 手性螺环磷酸催化合成光学活性四氢-β-咔啉衍生物的方法
JP6112625B2 (ja) 2011-12-14 2017-04-12 セラゴン ファーマシューティカルズ，インク． フッ素化したエストロゲン受容体モジュレーターおよびその使用
IN2014DN06169A (https=) * 2011-12-31 2015-08-21 Beigene Ltd
ES2672732T3 (es) * 2012-02-07 2018-06-15 Eolas Therapeutics Inc. Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina
SG11201405918XA (en) 2012-03-20 2014-10-30 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
PT2872482T (pt) 2012-07-13 2020-09-22 Oncternal Therapeutics Inc Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm)
BR112015018882B1 (pt) 2013-02-19 2021-09-14 Novartis Ag Derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo
JP2016517420A (ja) 2013-03-14 2016-06-16 セラゴン ファーマシューティカルズ， インク． 多環式エストロゲン受容体モジュレーター及びその使用
WO2015082990A1 (en) 2013-12-06 2015-06-11 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
CN104693211A (zh) 2013-12-10 2015-06-10 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
WO2015123355A1 (en) * 2014-02-12 2015-08-20 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
WO2015171527A1 (en) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
ES2687040T3 (es) 2014-05-16 2018-10-23 Idorsia Pharmaceuticals Ltd Derivados antibacterianos de quinazolin–4(3H)–ona
CN111978319B (zh) 2014-06-27 2023-08-11 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
CN107001371B (zh) 2014-10-09 2019-07-05 广东众生睿创生物科技有限公司 羟基嘌呤类化合物及其应用
MX2017013563A (es) 2015-04-21 2018-07-06 Gtx Inc LIGANDOS DEGRADADORES SELECTIVOS DEL RECEPTOR ANDROGí‰NICO (SARD) Y SUS Mí‰TODOS DE USO.
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
KR20180012853A (ko) * 2015-06-16 2018-02-06 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피페리딘 유도체 및 이의 제조 방법 및 약학적 용도
US10519148B2 (en) 2015-11-12 2019-12-31 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
CN109362222B (zh) * 2016-02-05 2021-03-19 益方生物科技(上海)股份有限公司 选择性雌激素受体降解物及其用途
CN112745316A (zh) 2016-04-01 2021-05-04 里科瑞尔姆Ip控股有限责任公司 雌激素受体调节剂
EP3468552A4 (en) 2016-06-10 2020-07-08 University of Tennessee Research Foundation SARD LIGANDS - SELECTIVE ANDROGEN RECEPTOR DEGRADATION COMPOUNDS - AND METHODS OF USE
WO2018001232A1 (zh) * 2016-06-29 2018-01-04 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
EP3522933B1 (en) * 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
WO2018130124A1 (zh) 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014191726A1 (en) * 2013-05-28 2014-12-04 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
WO2017172957A1 (en) 2017-10-05
JP2021176911A (ja) 2021-11-11
TW202235418A (zh) 2022-09-16
US10959989B2 (en) 2021-03-30
CN112679495A (zh) 2021-04-20
EP3442971A4 (en) 2020-01-01
CN112745316A (zh) 2021-05-04
EP3442971C0 (en) 2024-09-25
CN109311870A (zh) 2019-02-05
US20200261430A1 (en) 2020-08-20
JP6926189B2 (ja) 2021-08-25
IL261654A (en) 2018-10-31
KR20190002478A (ko) 2019-01-08
IL261654B (en) 2021-08-31
BR112018070161A2 (pt) 2019-02-12
EP3442971A1 (en) 2019-02-20
ES2991862T3 (es) 2024-12-05
AU2020294196A1 (en) 2021-01-28
AU2022204025A1 (en) 2022-06-30
US20190142811A1 (en) 2019-05-16
CN112679495B (zh) 2023-03-28
AU2020294196B2 (en) 2022-06-16
IL295050A (en) 2022-09-01
MX2022005780A (es) 2022-06-09
TWI746535B (zh) 2021-11-21
RU2018132037A (ru) 2020-05-12
US11065233B2 (en) 2021-07-20
EP3442971B1 (en) 2024-09-25
RU2018132037A3 (https=) 2020-05-15
AR108011A1 (es) 2018-07-04
AU2017242027A1 (en) 2018-10-11
JP2019515026A (ja) 2019-06-06
US20210330651A1 (en) 2021-10-28
US11065234B2 (en) 2021-07-20
CN113717170A (zh) 2021-11-30
IL285318A (en) 2021-09-30
SG11201807708SA (en) 2018-10-30
US20200261428A1 (en) 2020-08-20
CN109311870B (zh) 2021-09-21
US20200261429A1 (en) 2020-08-20
MX392461B (es) 2025-03-11
CA3017388C (en) 2024-03-12
KR20220071293A (ko) 2022-05-31
KR102401841B1 (ko) 2022-05-25
IL285318B (en) 2022-09-01
CA3017388A1 (en) 2017-10-05
TW201736334A (zh) 2017-10-16
MX2018011419A (es) 2019-06-06
RU2738646C2 (ru) 2020-12-15

Similar Documents

Publication Publication Date Title
AU2020294196B2 (en) Estrogen receptor modulators
KR20220119419A (ko) 복합제
EP4267578A1 (en) Estrogen receptor modulators
HK40064960A (en) Estrogen receptor modulators
HK40004087B (en) Estrogen receptor modulators
HK40004087A (en) Estrogen receptor modulators
BR112018070161B1 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso dos mesmos e método para inibir o crescimento de célula
HK40052769A (en) Estrogen receptor modulators
WO2019023481A1 (en) ANALOGUES OF ACRYLIC ACID

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: RECURIUM IP HOLDINGS, LLC

Free format text: FORMER NAME(S): ZENO ROYALTIES & MILESTONES, LLC

FGA Letters patent sealed or granted (standard patent)